Rwanda to get donor support for Rubella vaccines; iTunes cards for HPV vaccinations;

> Human trials on a new rheumatic fever vaccine have begun in New Zealand and Australia, which have some of the highest rates of rheumatic fever in the world. Item

> Rwanda will be the first country to get donor support to launch a vaccination campaign against Rubella after having success with its program attacking measles. Story

> Integrated BioTherapeutics ($IBT) is starting the first human trials on the bioterrorism vaccine STEBVAX, with a trial designed to enroll 28 healthy adults. Release

>  Vaccine developer Profectus BioSciences has contracted Althea Technologies to manufacture gram-scale quantities of plasmid DNA expressing IL-12 for Profectus vaccine work. Release

And Finally... East Carolina University is offering students a $20 iTunes card if they complete the vaccination cycle for the oft contracted genital human papillomavirus, which is a leading cause for certain types of cancers. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.